Has Venumadhav Kotla, MD received payments from drug or device companies?

Yes. Drug and device makers reported $23,741 in general payments to Venumadhav Kotla, MD across 457 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Venumadhav Kotla, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Venumadhav Kotla, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Venumadhav Kotla, MD

Medical Oncology · Gainesville, GANPI 1194983122

Payments from drug & device makers

$23,741in general payments, 2019–2025

Across 457 payments — averaging $51.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Takeda Pharmaceuticals U.S.A., Inc.$6K
Gilead$3K
Johnson & Johnson$2K
Novartis$2K
Daiichi Sankyo Inc.$1K
AstraZeneca$1K
plus $8K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Takeda Pharmaceuticals U.S.A., Inc.	13	$5,739
Gilead(2 entities)	16	$3,454
Johnson & Johnson	32	$2,235
Novartis	38	$2,117
Daiichi Sankyo Inc.	17	$1,401
AstraZeneca(2 entities)	24	$1,006
Merck	31	$754
Pfizer	33	$627
Bristol Myers Squibb	27	$575
Beigene USA, Inc.	3	$572
AbbVie	22	$478
Seagen Inc.	14	$400
Genentech USA, Inc.	16	$351
GSK	14	$311
Exelixis Inc.	10	$277
Sanofi	11	$258
Astellas Pharma US Inc	5	$235
Bayer	10	$226
E.r. Squibb & Sons, L.L.C.	11	$214
Novocure GmbH	1	$200
Amgen	10	$198
Eisai Inc.	8	$188
Lilly USA, LLC	7	$144
Incyte Corporation	6	$135
Regeneron Healthcare Solutions, Inc.	5	$121
Blueprint Medicines Corporation	5	$113
Karyopharm Therapeutics Inc.	5	$113
Sumitomo Pharma America, Inc.	4	$104
Foundation Medicine, Inc.	3	$88
Puma Biotechnology, Inc.	4	$81
Deciphera Pharmaceuticals Inc.	4	$80
AVEO Pharmaceuticals, Inc.	3	$65
Stemline Therapeutics Inc.	3	$61
Epizyme, Inc.	3	$60
Boehringer Ingelheim	2	$56
Morphosys, US Inc.	3	$53
Array Biopharma Inc	4	$51
CTI Biopharma Corp.	2	$51
Rigel Pharmaceuticals, Inc.	3	$48
ADC Therapeutics America, Inc.	2	$43
Pharmaessentia USA Corporation	1	$34
G1 Therapeutics, Inc.	2	$33
Agios Pharmaceuticals, Inc.	2	$30
Sobi, Inc	1	$28
Legend Biotech USA Inc.	1	$26
Adaptive Biotechnologies Corporation	1	$25
Blue Earth Diagnostics	1	$25
Taiho Oncology, Inc.	1	$23
Pharmacyclics LLC, An Abbvie Company	1	$22
EMD Serono, Inc.	1	$22
Organon	1	$21
Mirati Therapeutics, Inc.	1	$21
Biocompatibles, Inc.	1	$20
Geron Corporation	1	$18
Kyowa Kirin, Inc.	1	$17
Coherus Oncology, Inc.	1	$17
Servier Pharmaceuticals LLC	1	$16
Jazz Pharmaceuticals Inc.	1	$16
Macrogenics, Inc.	1	$14
Acrotech Biopharma Inc.	1	$13

How this compares

$23,741 in reported general payments places this provider in the 50th percentile of 68 medical oncology providers in Georgia.

See all medical oncology providers in Georgia →

Medicare billing

Part B allowed, 2024

$2,224,700

Medicare patients

295

Services billed

95,814

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Gainesville

Charles NashGainesville$258K
Andrew JohnsonGainesville$252K
Richard LociceroGainesville$33K
Yamin SunGainesville$17K
Shravanti MacherlaGainesville$14K
Timothy CareyGainesville$14K
Devi SampatGainesville$13K
Jennifer AndersonGainesville$12K
Nancy SteadGainesville$2K
Suresh RamalingamAtlanta$10.5M

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →